A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Brief summary

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

acronym

TRIUMPH-1

status

COMPLETED

phase

PHASE3

study type

INTERVENTIONAL

enrollment

2335

sponsor

Eli Lilly and Company

conditions

Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea

interventions

DRUG: Retatrutide; DRUG: Placebo

start date

2023-07-10

start date type

ACTUAL

primary completion date

2026-04-06

has results

false

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters